B2B Sales Pipeline Health Check:
7 Metrics That Actually Predict a Revenue Miss

Most B2B sales teams run pipeline reviews that look at two numbers: total pipeline value and pipeline coverage ratio. Both matter. Neither is sufficient. The teams that consistently hit plan are tracking a different set of metrics — ones that reveal structural risk rather than just surface volume.

Here are the seven pipeline health metrics that actually predict a revenue miss, and what each one tells you that standard CRM reporting does not.

Metric 1: Effective Coverage Ratio (Not Raw Coverage)

Raw pipeline coverage — total pipeline divided by revenue target — is the metric everyone starts with. Effective coverage adjusts that number for your actual historical win rate and the quality composition of your pipeline.

A raw 3× coverage ratio at a 22% win rate produces an effective coverage of 66% of target. That is a revenue miss built into the plan. Most companies never calculate it.

Benchmark: Effective coverage should be at or above 1.0× to have reasonable confidence in the plan. Anything below 0.85× means you are relying on upside scenarios to hit target.

Metric 2: Pipeline Concentration Index

The concentration index measures how much of your pipeline value is concentrated in your top three to five deals. High concentration means your revenue plan has a small number of single points of failure.

If your top three deals represent more than 40% of your total pipeline, a single slip changes your quarter materially. At 60% concentration, one deal slipping does not just threaten the quarter — it breaks it.

The fix for concentration risk is not to find one more big deal. It is to build pipeline depth across a larger number of qualified opportunities before the quarter begins. For more context on why concentration risk is one of the six structural failures behind revenue misses, see: Why B2B Companies Miss Their Revenue Target.

Metric 3: Deal Age vs Stage Progression

Average deal age measures how long deals have been in your pipeline. This metric only has meaning in context of stage progression — whether deals are moving forward relative to their age.

A deal that has been in the pipeline for twice its average sales cycle without a stage change is statistically unlikely to close. Its presence inflates your coverage ratio while contributing almost nothing to your actual close probability. These are sometimes called ghost deals — they exist in the CRM, they appear in the pipeline, and they are effectively lost.

Benchmark: Any deal whose age exceeds 1.5× your average sales cycle without a stage change in the last 30 days should be reviewed for demotion or closure.

Metric 4: Close Date Integrity Score

Close date integrity measures the proportion of deals in your pipeline that have had their close date pushed at least once. In most B2B sales teams, this number is higher than anyone wants to admit.

Research across B2B sales teams shows that deals with close dates pushed more than once are approximately 60% less likely to close than their stage suggests. When a pipeline has a high proportion of recycled close dates, the headline coverage ratio overstates real close probability significantly.

Benchmark: Less than 20% of in-period pipeline should have close dates that have been pushed more than once. Above 35% is a signal that pipeline hygiene has broken down.

Metric 5: Stage-to-Stage Conversion Rate

Win rate measures deals that close. Stage-to-stage conversion rate measures what happens at every step before close. A high win rate can mask a broken early-stage conversion that is starving your future pipeline. A low win rate is often a late-stage conversion problem — deals entering at a healthy rate but dying at proposal or negotiation.

Segment this metric by deal source, deal size, and sales rep. The pattern in which stage has the highest drop-off tells you exactly where your conversion architecture is broken.

Benchmarks: Discovery to qualified opportunity should convert above 40% for a healthy inbound pipeline, above 25% for outbound. Qualified opportunity to proposal above 50%. Proposal to close above 30%.

Metric 6: Pipeline Velocity

Pipeline velocity measures how fast deals are moving through your pipeline in dollar terms. It combines deal count, average deal size, win rate, and sales cycle length into a single number that represents weekly revenue generation rate.

Pipeline velocity is the metric that tells you whether you have enough time. A high coverage ratio with low velocity means the deals exist but will not close before the end of the period. Velocity gives you the time dimension that coverage ratio misses.

Metric 7: Revenue Leakage Rate

Revenue leakage is the gap between the revenue you should be closing based on your pipeline inputs and the revenue you actually close. It captures losses that happen in conversion, handoff, pricing, and post-sale — losses that never show up as lost deals in the CRM because they were never properly attributed.

The most common sources of revenue leakage in B2B are offer conversion failures at the pricing stage, handoff friction between marketing and sales, deals that move to procurement and stall, and discounting patterns that erode average deal size below the model. For a full breakdown of each type, see: What Is Revenue Leakage? How B2B Companies Lose Revenue They Already Earned.

Benchmark: If your closed revenue is consistently 15–25% below what your pipeline model predicts at the start of the quarter, you have a material revenue leakage problem that is distinct from win rate and coverage issues.

Putting It Together: The Pipeline Health Score

A complete pipeline health picture requires all seven metrics, not just coverage ratio. The companies that hit plan consistently are the ones who have built a weekly pipeline review process that checks all seven — and who have defined the specific thresholds at which each metric triggers a corrective action.

If you have not run a structured pipeline health check across all seven dimensions, you do not know whether your revenue plan will hit target. You know whether it looks like it will — which is a different thing entirely.